Efficacy of thoracic radiotherapy in patients with stage IIIB–IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment

Yen, Yu-Chun; Hsu, Han Lin; Chang, Jer‐Hwa; Wei, Lin; Chang, Yi‐Ping; Chang, Chin-Chih; Chow, Jyh Ming; Yuan, Kuo; Wu, Alexander T.H.; Wu, Szu-Yuan

doi:10.1016/j.radonc.2018.03.007

Cited by 29 publications

(33 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Taiwan Cancer Registry Database (TCRD) from the Collaboration Center of Health Information application contains detailed cancer‐related information, and the quality and precision of codes in Taiwan were verified and proven by previous studies …”

Section: Methodsmentioning

confidence: 77%

Age comorbidity scores as risk factors for 90‐day mortality in patients with a pancreatic head adenocarcinoma receiving a pancreaticoduodenectomy: A National Population‐Based Study

et al. 2019

View full text Add to dashboard Cite

Background:To estimate easily assessed preoperative factors for predicting 90day mortality in patients with a pancreatic head adenocarcinoma (PHA) receiving a pancreaticoduodenectomy. Methods: We analyzed data from the Taiwan Cancer Registry Database of patients with a PHA who received a pancreaticoduodenectomy. Basic demographic characteristics, including gender and age, were categorized. The selection of preoperative comorbidities was based on the preoperative American Society of Anesthesiologists score and Charlson comorbidity index. Results: We enrolled 8490 patients with a PHA who received a pancreaticoduodenectomy without distant metastasis. Currently, a pancreaticoduodenectomy for a PHA achieves an overall 90-day mortality rate of 8.39%. Univariate and multivariate Cox regression analyses indicated that an older age (65-74 and ≥75 years) and specific comorbidities (chronic obstructive pulmonary disease, chronic kidney disease, dementia, and sepsis) were significant independent prognostic factors for predicting 90-day mortality after a pancreaticoduodenectomy. After adjustment, the adjusted 572 |

show abstract

Section: Methodsmentioning

confidence: 77%

Age comorbidity scores as risk factors for 90‐day mortality in patients with a pancreatic head adenocarcinoma receiving a pancreaticoduodenectomy: A National Population‐Based Study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Our protocols were reviewed and approved by the Institutional Review Board of Taipei Medical University (TMU-JIRB 201702019). The Collaboration Center of Health Information Application TCRD contains detailed cancer-related information regarding the clinical stage and the RT dose, RT technique, and chemotherapy regimen used [19][20][21][22][23][24][25][26][27][28]. The diagnoses of selected patients were confirmed on the basis of pathological data.…”

Section: Methodsmentioning

confidence: 99%

Outcomes for Elderly Patients Aged 70 to 80 Years or Older with Locally Advanced Oral Cavity Squamous Cell Carcinoma: A Propensity Score–Matched, Nationwide, Oldest Old Patient–Based Cohort Study

Shia

Qin

Lin

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Purpose: Although clinicians encounter patients aged ≥70 years with locally advanced oral cavity squamous cell carcinoma (LA-OCSCC), no evidence is available to facilitate decision making regarding treatment for this elderly population. Methods: We selected elderly (≥70 years) patients from the Taiwan Cancer Registry database who had received a diagnosis of LA-OCSCC. Propensity score matching was performed. Cox proportional hazards model curves were used to analyze all-cause mortality in patients in different age groups receiving different treatments. Results: The matching process yielded a final cohort of 976 patients in concurrent chemoradiotherapy (CCRT), non-treatment, radiotherapy (RT) alone, and surgery cohorts who were eligible for further analysis. After stratified analysis, the adjusted hazard ratios (aHRs) (95% confidence intervals [CIs]) derived for surgery, RT alone, and non-treatment compared with CCRT were 0.66 (0.52 to 0.83), 1.02 (0.81 to 1.28), and 1.52 (1.21 to 1.91), respectively, in patients aged 70 to 80 years. In the oldest patients (aged >80 years), multivariate analysis indicated that the results of surgery or RT alone were nonsignificant compared with those of CCRT. The aHR (95% CI) derived for the highest mortality was 1.81 (1.11 to 2.40) for non-treatment compared with CCRT. Conclusions: Surgery for elderly patients with LA-OCSCC is associated with a significant survival benefit, but the association is nonsignificant in the oldest elderly patients. No survival differences were observed between RT alone and CCRT in these elderly patients. Non-treatment should not be an option for these patients.

show abstract

“…The Taiwan Cancer Registry database (TCRD) established by the Collaboration Center of Health Information Application contains detailed cancer-related information [15][16][17][18][19][20][21][22][23][24]. This database thus constituted the source of data for the present study.…”

Section: Data Sourcementioning

confidence: 99%

Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study

Chang

Yuan

et al. 2019

Cancers

Self Cite

View full text Add to dashboard Cite

Purpose: To determine the optimal adjuvant chemotherapy regimen for patients with high-risk stage II or III colon adenocarcinoma, we conducted this propensity score-matched, nationwide, population-based cohort study to estimate the effects of adjuvant treatments in high-risk stage II or III colon adenocarcinoma. Patients and Methods: Using propensity score matching, we minimized the confounding effects of sex, age, pathologic stage, tumor location, total chemotherapy cycles, and Charlson comorbidity index scores on adjuvant treatment outcomes in patients with high-risk stage II or III resectable colon adenocarcinoma. We selected the patients from the Taiwan Cancer Registry database and divided them into four groups: Group 1, comprising patients who received surgery alone; group 2, comprising those who received adjuvant fluoropyrimidine alone; group 3, comprising those who received adjuvant oxaliplatin-fluoropyrimidine-leucovorin (FOLFOX); and group 4, comprising those who received adjuvant folinic acid-fluorouracil-irinotecan (FOLFIRI). Results: In both univariate and multivariate Cox regression analyses, the adjusted hazard ratios (aHRs, as well as the 95% confidence intervals (Cis)) for mortality observed for groups 1, 2, and 4 relative to group 3 were 1.55 (1.32 to 1.82), 1.22 (1.05 to 1.43), and 2.97 (2.43 to 3.63), respectively. After a stratified subgroup analysis for high-risk stage II colon adenocarcinoma, we noted that the aHR (95% CI) for mortality for group 2 relative to group 3 was 0.52 (0.30 to 0.89). Conclusions: Adjuvant fluoropyrimidine alone is the most optimal regimen for patients with high-risk stage II colon adenocarcinoma compared with the other adjuvant chemotherapy regimens. Adjuvant FOLFOX can serve as an optimal regimen for patients with pathologic stage III colon adenocarcinoma, regardless of age, sex, or tumor location.

show abstract

Efficacy of thoracic radiotherapy in patients with stage IIIB–IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment

Cited by 29 publications

References 43 publications

Age comorbidity scores as risk factors for 90‐day mortality in patients with a pancreatic head adenocarcinoma receiving a pancreaticoduodenectomy: A National Population‐Based Study

Age comorbidity scores as risk factors for 90‐day mortality in patients with a pancreatic head adenocarcinoma receiving a pancreaticoduodenectomy: A National Population‐Based Study

Outcomes for Elderly Patients Aged 70 to 80 Years or Older with Locally Advanced Oral Cavity Squamous Cell Carcinoma: A Propensity Score–Matched, Nationwide, Oldest Old Patient–Based Cohort Study

Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study

Contact Info

Product

Resources

About